



FOR IMMEDIATE RELEASE

Media Contact: Melissa Blacketer. mblacketer@ascp.com

ASCP Responds to 2026 Update to the National Plan to Address Alzheimer's Disease and Related Dementias

Alexandria, VA – October 22, 2026 – Chad Worz, PharmD, issued the following statement on behalf of the American Society of Consultant Pharmacists (ASCP) regarding the 2026 Update to the National Plan to Address Alzheimer's Disease and Related Dementias:

"ASCP and our age-friendly pharmacists and pharmacies applaud the U.S. Department of Health and Human Services' (HHS) renewed and refocused efforts to address Alzheimer's disease and related dementias. The update unveiled today takes bold and constructive steps to support individuals and families living with these devastating diseases. As medication management professionals, we appreciate the emphasis on accelerating innovation in treatment and prevention. While finding a cure remains central to our shared mission, many individuals living with these diseases today can and do benefit from advances in treatment and care.

"As pharmacists dedicated to the care of older adults, including transitions of care, we are particularly pleased to see the plan's focus on advancing high-value care across healthcare settings. Individuals living with Alzheimer's disease and related dementias often transition between care settings, making coordinated, high-quality care essential to ensuring successful transitions and maintaining the best possible quality of life.

"ASCP applauds the leadership of HHS and the Centers for Medicare & Medicaid Services (CMS) in developing this plan. We stand ready to collaborate with these leaders on its implementation to improve the care and quality of life of individuals living with Alzheimer's disease and related dementias."

About ASCP:

[The American Society of Consultant Pharmacists](#) (ASCP) is the only international professional society devoted to optimal medication management and improved health outcomes for all older persons. ASCP's members manage and improve drug therapy and improve the quality of life of geriatric patients and other individuals residing in a variety of environments, including nursing

facilities, sub-acute care and assisted living facilities, psychiatric hospitals, hospice programs, and home and community-based care.

###